Sarepta stock rises as Jefferies reiterates Buy rating after Elevidys shipments resume

Sarepta Therapeutics (SRPT) has resumed shipments of its Duchenne muscular dystrophy drug Elevidys, following an FDA determination that a patient death was unrelated, albeit with new black box warnings for liver risks. This regulatory clearance, combined with strong Q2 earnings that significantly exceeded analyst expectations ($611.1M revenue, $2.02 EPS), has led Jefferies to reiterate its Buy rating and project $1.4 billion in annual sales by 2027. While the stock has seen a substantial decline over the past year and profitability challenges persist, the improved sales outlook for Elevidys has prompted multiple analyst upgrades and price target increases, signaling a more positive mid-term revenue trajectory for Sarepta.

Analysis

Sarepta Therapeutics (SRPT) has received a significant operational catalyst with the FDA's clearance to resume shipments of its Duchenne muscular dystrophy (DMD) drug, Elevidys, after determining a patient death was unrelated to the treatment. This decision substantially de-risks the near-term revenue outlook for the drug, which is now projected by Jefferies to contribute to potential annual sales of $1.4 billion by 2027. This positive regulatory development is compounded by exceptionally strong second-quarter financial results, where Sarepta reported revenue of $611.1 million and adjusted EPS of $2.02, decisively beating consensus estimates of $532.86 million and $0.70, respectively. The company's revenue growth is robust, at 68% year-over-year for the quarter. However, significant headwinds remain; the resumed shipments come with a new black box warning for acute liver injury, a material risk highlighted by TD Cowen's Hold rating and $17.00 price target. This contrasts sharply with more bullish outlooks from Jefferies ($35.00 PT), Freedom Broker ($37.00 PT), and Wells Fargo ($50.00 PT), creating a wide divergence in analyst sentiment. Despite the recent positive momentum, the stock is down over 85% in the past year, and analysts anticipate profitability challenges will persist in the near term.

Key Decisions for Investors

• Investors should weigh the significant near-term revenue catalyst from the resumption of Elevidys shipments and strong Q2 earnings against the material risk posed by the new black box warning for liver injury, which could temper commercial adoption.
• Given the stock's 85% decline over the past year, the current situation may present a speculative buying opportunity for those with a high risk tolerance, particularly as several analysts have issued price targets substantially above the current trading level.
• It is critical to monitor the company's progress toward profitability, as strong top-line growth has not yet translated to sustained earnings, and to watch for any further data or regulatory commentary regarding Elevidys's liver safety profile.